本页面由Tiger Trade Technology Pte. Ltd.提供服务

Kailera Therapeutics, Inc.

16.54
-0.6300-3.67%
成交量:54.95万
成交额:914.75万
市值:21.43亿
市盈率:-7.34
高:17.16
开:17.14
低:16.37
收:17.17
52周最高:28.23
52周最低:16.37
股本:1.30亿
流通股本:4,492.19万
量比:0.55
换手率:1.22%
股息:- -
股息率:- -
每股收益(TTM):-2.2543
每股收益(LYR):-7,819.9811
净资产收益率:-36.90%
总资产收益率:-22.73%
市净率:1.92
市盈率(LYR):0.00

数据加载中...

公司资料

公司名字:
Kailera Therapeutics, Inc.
交易所:
NASDAQ
成立时间:
2024
员工人数:
- -
公司地址:
180 Third Avenue,4th Floor,Waltham,Massachusetts,United States
邮编:
02451
电话:
传真:
- -
简介:
Kailera Therapeutics, Inc.于2024年5月8日根据特拉华州法律注册成立。该公司是一家处于临床阶段的生物技术公司,致力于通过推进多元化的研发管线,引领肥胖症治疗的新时代。目前,该公司正在快速推进四款处于临床阶段的候选产品,这些产品利用多种基于胰高血糖素样肽-1 (GLP-1) 的作用机制和给药途径。

董事

名称
职位
John F. Milligan
Chairman and Director
Ronald C. Renaud, Jr.
Chief Executive Officer,Director and President
Adam Koppel
Independent Director
Andrew Kaplan
Independent Director
Christopher Hite
Independent Director
Frank Clyburn, Jr.
Independent Director
Martin Mackay
Independent Director
Michael Gladstone
Independent Director
Yuting Liu
Independent Director

股东

名称
职位
Ronald C. Renaud, Jr.
Chief Executive Officer,Director and President
Paul Burgess
Chief Business Officer and Chief Operating Officer
Douglas Pagán
Chief Financial Officer
Jamie Coleman
Chief Commercial Officer
Paula Cloghessy
Chief People Officer
Scott Akamine
Chief Legal Officer and Secretary
Scott Wasserman
Chief Medical Officer